RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa
a study on Retinitis Pigmentosa
Advanced Retinitis Pigmentosagene therapyoptogeneticschannelrhodopsinretinaretinitis pigmentosaRetinitisRST-001
Lead Scientist at UCSF
- Jacque Duncan
Retinitis pigmentosa (RP) affects about 1 in 3,500 people worldwide. Age-related macular degeneration (AMD) affects as many as 1 in 4 people by the age of 75 and is the leading cause of blindness in people over age 50 in the United States. Both RP and AMD have a hereditary basis, and currently, there is no cure for either of these types of hereditary retinal degeneration.
- accepting new patients
- Start Date
- Completion Date
- Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR-CTRegistration@Allergan.com for assistance.
- Phase 1/2
- Study Type
- Last Updated